reblogged from
http://mbcnbuzz.wordpress.com/2014/05/17/wheres-my-clinical-trial/
Where’s my clinical trial?
by Ginny Knackmuhs, VP of MBCN
I’m one of the lucky ones, I know.
Although I was diagnosed with metastatic triple negative breast
cancer 5 years ago, I have been on the same treatment regimen since
then. No progression, just blessed stability. I hesitate to write that
sentence or say it out loud—afraid I’ll jinx my good fortune, always
mindful of the next scan around the corner, when everything can change
in an instant.
Metastatic breast cancer (MBC), also sometimes called advanced breast
cancer or Stage IV disease, is incurable, but still treatable.
Oncologists like to say it is a chronic disease, but with an average
life expectancy of 2.5 to 3 years, it certainly isn’t chronic yet. Give
us 10 or 20 years of stable treatment and quality of life and we’ll be
happy to call it chronic.
Next
week I’m going to ASCO in Chicago, the annual meeting of the American
Society of Clinical Oncologists. I’ve reviewed the agenda. Interesting
and promising research will be reported on, not just in breast cancer
but across the cancer disease spectrum.
One thing I didn’t find? Research papers about me, about those of us
who are stable or have been NED (no evidence of disease) for years. We
are defying statistics and maintaining that fragile, illusive state of
tumor dormancy. Isn’t any researcher interested in running my genomic
profile, sampling my blood and tumor tissue, establishing a baseline of a
mets patient who is doing well? Isn’t it worth looking at patterns that
might emerge from studying all of us at this stage of our disease? Why
are we among the enviable few of patients living with metastatic
disease? Not to collect our data seems like a lost opportunity, a cache
of valuable information that should be captured.
Dr. Susan Love in speaking about her research foundation, often cites
an anecdote about aviation experts in World War II. They were studying
downed planes until someone suggested this: “Why not look at the planes
that stayed in the air? ”
This is the 50
th anniversary of ASCO and visiting
cancerprogress.net
reveals milestones in cancer research and treatment. Yet, there is
still much room for improvement. 40,000 women and men die every year
from breast cancer—metastatic breast cancer. That number is essentially
unchanged in the last decade. 110 people each day, every day, a daily
catastrophe that doesn’t make headlines. 110 people dying every day; 770
dying every week; over 3000 every month– from the cancer, which is
still viewed as one of the ‘better’ cancers to get. We can and must do
better. Even Nancy Brinker tweeted this week: “So much more work to do
together to end MBC.”
So, ASCO researchers, I am ready and willing. Study me. Collect my
data. I know there are others out there in my situation. Last month I
spoke at a program at NYU and a few people in the audience spoke up and
said they had been NED for years. Sign us up, ASCO. We’re ready to help.
I’m not a researcher or clinician, just a patient advocate, a woman
living with metastatic breast cancer, who is attending the ASCO 2014
meeting and will take every opportunity to ask: Where’s my clinical
trial?